Format

Send to

Choose Destination
See comment in PubMed Commons below
Science. 2013 May 24;340(6135):924-e. doi: 10.1126/science.1233937.

Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Author information

1
VIB Center for the Biology of Disease, Leuven, Belgium.

Abstract

Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) tested bexarotene as a potential β-amyloid-lowering drug for Alzheimer's disease (AD). We were not able to reproduce the described effects in several animal models. Drug formulation appears very critical. Our data call for extreme caution when considering this compound for use in AD patients.

PMID:
23704554
DOI:
10.1126/science.1233937
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center